RIAMET

Given its efficacy in the treatment of uncomplicated malaria, particularly in the case of multidrug-resistant strains, and a lower risk of developing resistance with combinations containing artemisinin derivatives compared with traditional monotherapies, particularly in children and in malaria-endemic areas (mainly French Guiana and Mayotte), the proprietary medicinal product RIAMET, like the proprietary medicinal product EURARTESIM, provides a minor improvement in actual benefit (IAB IV) in the treatment of uncomplicated Plasmodium falciparum malaria.